×
戻る Agenda
A Collaborative Cross-Company Pediatric Platform Trial in Pediatric Crohn’s Disease Using an Innovative Bayesian Analysis
Session Chair(s)
Robert "Skip" Nelson, MD, PhD
Executive Director, Pediatric Drug Development (CHILD)
Johnson & Johnson, United States
Innovative approaches to pediatric drug development are needed to reduce the delay between adult and pediatric marketing approval. This session presents a cross-company pediatric platform trial in Crohn's disease using a Bayesian analysis.
Learning Objective : Identify some of the recruitment challenges in pediatric drug development; Identify the role of platform trials in addressing these challenges; Discuss the clinical, scientific, regulatory, and operational challenges in designing and implementing a cross-company pediatric platform trial.
Speaker(s)
Industry Update
Laurie Conklin, MD
Johnson and Johnson Innovative Medicine, United States
Senior Director, Office of Chief Medical Officer
Industry Update
Wendy Komocsar
Eli Lilly and Company , United States
Research Advisor, Immunology
Industry Update
Forrest Williamson, PhD, MS
Eli Lilly and Company, United States
Director of Pediatrics, Statistical Innovation Center